Dopamine agonist therapy in hyperprolactinemia

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 44, Issue 12 SUPPL., 1999, Pages 1105-1110

  Webster, Jonathan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonists; Hyperprolactinemia; Prolactinoma; Quinagolide

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRISTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; METERGOLINE; PERGOLIDE; PROLACTIN; QUINAGOLIDE; TERGURIDE;

ARTICLE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERPROLACTINEMIA; NAUSEA; PLASMA HALF LIFE; PRIORITY JOURNAL; VERTIGO;

AMINOQUINOLINES; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0033403487     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ho KY, Thorner MO: Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988;36: 67-82
2. Crosignani PG, Ferrari C: Dopaminergic treatments for hyperprolactinaemia. Clin Obstet Gynecol 1990;4:441-455
3. Molitch ME: Management of prolactinomas. Ann Rev Med 1989;41:255-232
4. Bevan JS, Webster J, Burke CW, et al: Dopamine agonists and pituitary tumor shrinkage. Endocrinol Rev 1992;13: 220-240
5. Webster J, Piscitelli G, Polli A, et al: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909
6. Lamberts SW, Quik RF: A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991;72: 635-641
7. Mattox JH, Bernstein J, Buckman MT: Control of hyperprolactinemia with pergolide. Int J Fertil 1986;30:39-43
8. Bouloux PM, Besser GM, Grossman, et al: Clinical evaluation of lysuride in the management of hyperprolactinaemia. Br Med J (Clin Res Ed) 1987;294:1323-1324
9. Caballero A Sr, Mena P, Caballero-Ciaz JL, et al: Metergoline as an inhibitor of prolactin release. J Reprod Med 1987;32: 115-119
10. Venturini PL, Horowski R, Fasce V, et al: Suppression of puerperal lactation by terguride: A double-blind study. Gynecol Obstet Invest 1988;19:225-229
11. De Aloysio D, Pamparana F, Zanotti A, et al: Dihydroergocristine in stopping lactation: Double blind study vs bromocriptine. Gynecol Endocrinol 1988;2:67-71
12. Rains CP, Bryson HM, Fitton A: Cabergoline: A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation. Drugs 1995;49:255-279
13. Mattei AM, Ferrari C, Baroldi P, et al: Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988;66:193-198
14. Webster J, Piscitelli G, Polli A, et al: Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicentre study. Clin Endocrinol 1992;37:534-541
15. Webster J, Piscitelli G, Polli A, et al: The efficacy and tolerability of cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled multicentre study. Clin Endocrinol 1993;39:323-329
16. Muratori M, Arosio M, Gambino G, et al. Use of cabergoline in the long term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537-546
17. Venetikou MS, Burrin JM, Woods CA, et al: Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro. Acta Endocrinol 1987;116:287-292
18. Rasmussen C, Bergh T, Wide L, et al: CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol 1987;26:321-326
19. Homburg R, West C, Brownell J, et al: A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol 1990;32:565-571
20. Verhelst JA, Fraud AL, Touzel R, et al: Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinaemia: A double blind study. Acta Endocrinol 1991;125:385-391
21. van der Heijden PFM, de Wit W, Brownell J, et al: CV205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obs Gynecol Reprod Biol 1991;40:111-118
22. Giusti M, Porcella E, Carraro A, et al: A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients. J Endocrinol Invest 1994;17:51-57
23. Vilar L, Burke CW: Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol 1994;41:821-826
24. Merola B, Sarnacchiaro F, Colao A, et al: Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994;8:175-181
25. Razzaq R, O'Halloran DJ, Beardwell CG, et al: The effects of CV 205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. Horm Res 1993;39: 218-222
26. Ferrari C, Paracchi A, Mattei AM, et al: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489-494
27. Jones TH, Fraser RB: Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. Br J Obstet Gynaecol 1994;101:349-350
28. Page SR, Nussey SS: Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient. J Obstet Gynaecol 1989;10:156-157
29. Ciccarelli E, Giusti M, Miola C, et al: Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-728
30. Delgrange E, Maiter D, Donkier J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134: 454-456
31. Morange I, Barlier A, Pellegrini, et al: Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;134:413-420
32. Biller BMK, Molitch M, Vance ML, et al: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-2343
33. Colao A, De Rosa M, Sarnacchiaro F, et al: Chronic treatment with CV 205-502 restored the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996;135:548-552
34. Colao A, Di Sarno, Landi ML, et al: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574-3579
35. Colao A, Loche S, Cappa M, et al: Prolactinomas in children and adolescents: Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777-2780
36. Colao A, Di Sarno A, Sarnacchiaro FC, et al: Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline therapy. J Clin Endocrinol Metab 1997;82: 876-883
37. Delgrange E, Donckier J: Prolactinomas apparently resistant to standard dopamine agonists respond to chronic cabergoline therapy. J Clin Endocrinol Metab 1997;82:2755-2756
38. Colao A, Lombardi G: Prolactinomas apparently resistant to standard dopamine agonists respond to chronic cabergoline therapy (lett). J Clin Endocrinol Metab 1997;82:2756